Recordati S.p.A. (REC.MI): analysis and signal as of September 3, 2026
In short
The system issues no signal on Recordati S.p.A. (REC.MI), with a score of 3.5 and a vote of 3/3. This absence of a signal is explained by fundamentals that cannot be verified for 2026 and by a neutral technical signal between the MM50 and MM200 moving averages.
- Current signal
- no signal (vote 3/3) divergence
- Deterministic score
- +3.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : neutral, price : neutral, risks : positive
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower) | -1.5 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
Thesis
The thesis rests on the defensive healthcare theme, supported by the current macroeconomic regime. The weighted deterministic verdict comes out at +5,00 but it is contradicted by the lack of verification of the 2026 news flows. No verifiable fundamental data allows going beyond caution. The technical signal, neutral with respect to the MM50 and MM200 moving averages, provides no catalyst in favour of a bullish or bearish direction.
Bull case
The main bullish argument rests on membership in the European specialty pharmaceutical sector, broadened by the Recordati Rare Diseases branch. The company benefits from a defensible competitive advantage, backed by a set of niche patents. Its defensive profile aligns with a Cboe risk regime described as neutral. This combination gives the stock relative visibility within the defensive healthcare theme, supported by the macroeconomic regime.
Bear case
The main bearish argument stresses the total absence of live verification of the first-half 2026 fundamentals. Share repurchases are not confirmed. The overnight profile over 2 years, negative in intraday, shows a rise not confirmed by institutional flows during the session. This divergence between overnight performance and daytime trading constitutes a sign of fragility in the bullish move.
Scenarios
The bullish scenario, judged least probable, assumes a sector consolidation catalyst such as a takeover offer on the stock. The central scenario remains the most probable and describes a move within a tight range, with no clear direction. The bearish scenario, of intermediate probability, would correspond to a deterioration in the company's earnings forecasts.
Risks
The main risk lies in the lack of verified data. The first-half 2026 fundamentals have undergone no live verification and share repurchases remain unconfirmed. A deterioration in earnings forecasts would invalidate the bullish reading. On the technical side, a closing break below the invalidation level defined by the model, or a break of the 200-session moving average, would call the thesis into question. The non-confirmation of institutional flows during the session increases the risk of a pullback.
Upcoming catalysts
| Date | Description |
|---|---|
| T3 2026 Results - growth in rare disease segments |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| no signal (3/3) | Personal analysis, it does not constitute investment advice. | |
| no signal (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What is the system's signal on Recordati S.p.A.?
The system issues no signal on this stock, despite a vote of 3/3 and a score of 3.5. This neutrality results from a trade-off between a weighted deterministic verdict of +5,00 and the lack of verification of the 2026 news flows. Recent fundamentals are therefore not confirmed, which leads the model to identify no exploitable bullish or bearish direction.
Why is the defensive healthcare theme not enough to trigger a signal?
The macroeconomic regime does support defensive healthcare and the European specialty pharmaceutical sector remains promising. However, no verifiable fundamental data allows going beyond caution. The first-half 2026 fundamentals have undergone no live verification and the technical signal, neutral between MM50 and MM200, provides no catalyst. The model therefore favours the absence of a signal rather than an unsupported direction.
What does the negative overnight profile mentioned in the analysis mean?
The system observes a negative overnight profile over 2 years in intraday terms for this stock. This means that the recorded rise is not confirmed by institutional flows occurring during the session. This divergence between overnight performance and daytime trading is interpreted as a sign of fragility in the bullish move. It weighs on the decision not to generate a signal.
What events would activate the bullish scenario or the bearish scenario?
The bullish scenario, judged least probable, would be activated by a sector consolidation catalyst, such as a takeover offer on the stock. The bearish scenario, of intermediate probability, would correspond to a deterioration in the earnings forecasts published by the company. Between the two, the central scenario remains the most probable and describes a move in a tight range, with no clear direction.
Does this analysis constitute investment advice?
No, this is an informative analysis produced by a personal market data processing system. It describes a signal, a thesis, arguments and scenarios without formulating any personalised recommendation. The information retained comes from an automated verdict, not verified live for the year 2026. The reader retains full responsibility for their decisions and for adapting them to their own situation.
Sources
No official filing is attached to this stock in the database to date. The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 3, 2026; this page was completed on September 3, 2026 at 22:01 (UTC).
- Interests: no position in the stock analysed (REC.MI) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology